Bristol-Myers Squibb ($BMY) inked a pair of deals to broaden its immuno-oncology efforts: It will partner with Incyte ($INCY) in testing the latter's drug candidate INCB24360 with its own PD-1 drug nivolumab. And it agreed to pay up to $1.24 billion to CytomX in a deal for up to four new "probody" drug candidates. Report